AbbVie Agrees To Buy Apogee Therapeutics For $10.9 Billion

AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash, a deal that expands the drugmaker’s immunology pipeline and adds a long-dated asset as it works to sustain growth beyond Humira.

Under the terms reported on Monday, June 22, Apogee shareholders will receive $135.11 per share in cash. That price represents a 49% premium to Apogee’s prior close, according to the reports.

The acquisition was reported and confirmed the same day by multiple outlets, including the Financial Times, The Wall Street Journal, Barron’s and Investor’s Business Daily. Barron’s said both boards approved the transaction and that the deal is expected to close in the third quarter of 2026.

Why AbbVie Is Buying

AbbVie has been managing the revenue transition away from Humira, its former blockbuster. The company has leaned more heavily on Skyrizi and Rinvoq, but the Apogee deal shows it is still willing to spend heavily to reinforce its immunology franchise.

AbbVie chief executive Robert Michael said Apogee’s pipeline adds highly differentiated clinical-stage assets, according to the Financial Times report. The message is clear: AbbVie is paying for future growth in a therapeutic area where it already has a major commercial position.

Apogee’s lead asset is zumilokibart, an experimental treatment being developed for atopic dermatitis and other inflammatory diseases such as asthma. That makes the target strategically relevant for AbbVie, which already has a large footprint in inflammatory disease and immunology.

The move also fits a broader pattern in biopharma, where large drugmakers are using acquisitions to refill pipelines and extend the life of their growth franchises. In this case, AbbVie is effectively buying time and optionality in a market it knows well.

Deal Terms And Timing

The reports said the acquisition is a cash transaction and that the boards of both companies have approved it. The stated timetable points to a closing in the third quarter of 2026, although the companies have not yet provided a more exact date.

The initial reports did not disclose termination fees, financing details or other mechanics that may appear later in SEC filings and merger documents. Those filings should also clarify any remaining conditions needed before closing.

Investor’s Business Daily said the announcement sent Apogee shares sharply higher and also lifted AbbVie stock in early trading. That response suggests the market sees strategic logic in AbbVie’s willingness to pay up for a differentiated immunology program.

The deal gives Apogee investors a large cash exit at a substantial premium, while AbbVie gets a chance to broaden its long-term lineup in atopic dermatitis and related inflammatory diseases. It also raises the competitive stakes in a market that includes companies such as Sanofi and Regeneron.

What comes next is straightforward: the formal merger filing, any investor presentation and later regulatory disclosures should fill in the structure and risk factors. Until then, the core story is already clear. AbbVie is spending aggressively to defend its immunology franchise and replace future growth pressure with a new pipeline bet.